Tibotec, Inc clinical trials
Acquired by Johnson & Johnson, Apr 2002 · source ↗
The registry lists 6 studies whose lead sponsor is Tibotec, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 30, 2015.
Before and after it joined Johnson & Johnson
- First submitted before Tibotec, Inc became part of Johnson & Johnson
- 0
- First submitted after Tibotec, Inc became part of Johnson & Johnson
- 6
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Tibotec, Inc6 studies
Something wrong with this grouping? Tell us on the Johnson & Johnson page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Johnson & Johnson studies →
- Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received TreatmentCompletedNCT00757783Phase 4
Sponsor listed in the registry: Tibotec, Inc · First submitted after Tibotec, Inc became part of Johnson & Johnson
- A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).CompletedNCT00534352Phase 2
Sponsor listed in the registry: Tibotec, Inc · First submitted after Tibotec, Inc became part of Johnson & Johnson
- GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.CompletedNCT00381303Phase 3
Sponsor listed in the registry: Tibotec, Inc · First submitted after Tibotec, Inc became part of Johnson & Johnson
- A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced PatientsCompletedNCT01199939Phase 2
Sponsor listed in the registry: Tibotec, Inc · First submitted after Tibotec, Inc became part of Johnson & Johnson
- A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female VolunteersCompletedNCT01268839Phase 1
Sponsor listed in the registry: Tibotec, Inc · First submitted after Tibotec, Inc became part of Johnson & Johnson
- Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.CompletedNCT00460746Phase 3
Sponsor listed in the registry: Tibotec, Inc · First submitted after Tibotec, Inc became part of Johnson & Johnson